Stay updated on Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial page
- Check3 days agoChange DetectedRevision: v3.6.2 replaces v3.6.0 on the page, indicating a backend software update; no visible content changes are implied by this revision tag.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedThe SOPHIA study page now indicates that it is no longer recruiting participants. Enrollment is closed.SummaryDifference0.2%

- Check25 days agoChange DetectedThe page's revision tag was updated to v3.5.5, replacing the former v3.5.4 tag to reflect a new version of the page.SummaryDifference0.0%

- Check46 days agoChange DetectedThe page revision number was updated from 3.5.3 to 3.5.4, indicating a new iteration of the record. This likely reflects minor edits or housekeeping rather than changes to study data or eligibility.SummaryDifference0.0%

- Check67 days agoChange DetectedThe page’s locations list has a Denmark entry updated to use “Region Sjælland” instead of “Zeeland,” indicating a correction/standardization of regional naming. The revision label at the bottom is also updated, reflecting a site/version update rather than a substantive study change.SummaryDifference0.1%

- Check75 days agoChange DetectedRevision: v3.5.2 is now shown on the page, replacing the previous Revision: v3.5.0.SummaryDifference0.0%

Stay in the know with updates to Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Margetuximab vs Trastuzumab in HER2+ Metastatic Breast Cancer Clinical Trial page.